Ken Griffin Corcept Therapeutics Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$29.51 - $46.26 $306,904 - $481,104	-10,400 Reduced 14.65%	60,600 $2.8 Million
Q2 2024 Aug 14, 2024	SELL	$22.21 - $34.48 $364,244 - $565,472	-16,400 Reduced 18.76%	71,000 $2.31 Million
Q1 2024 May 15, 2024	BUY	$21.1 - $27.46 $1.21 Million - $1.57 Million	57,200 Added 189.4%	87,400 $2.2 Million
Q4 2023 Feb 14, 2024	BUY	$24.82 - $32.88 $600,644 - $795,696	24,200 Added 403.33%	30,200 $980,000
Q3 2023 Nov 14, 2023	BUY	$21.97 - $33.8 $57,122 - $87,879	2,600 Added 76.47%	6,000 $163,000
Q2 2023 Aug 14, 2023	SELL	$21.44 - $25.15 $398,784 - $467,790	-18,600 Reduced 84.55%	3,400 $75,000
Q1 2023 May 15, 2023	SELL	$19.2 - $24.47 $1.03 Million - $1.31 Million	-53,700 Reduced 70.94%	22,000 $476,000
Q4 2022 Feb 14, 2023	BUY	$19.95 - $29.96 $917,700 - $1.38 Million	46,000 Added 154.88%	75,700 $1.54 Million
Q3 2022 Nov 14, 2022	BUY	$24.7 - $29.12 $350,740 - $413,504	14,200 Added 91.61%	29,700 $762,000

347

86.6M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.18B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.